GPOs May Spurn Anti-Competitive Contracts After Masimo v. Tyco – MDMA
This article was originally published in The Gray Sheet
Executive Summary
Masimo believes its $420 mil. legal victory over Tyco will spur large manufacturers and GPOs to gradually alter their business practices, resulting in long-term cost savings for hospitals
You may also be interested in...
GPO Safe Harbor Vulnerable? Senate Inquiry Targets Hospital Purchasers
Senators with important ties to health reform negotiations have launched an inquiry into the common hospital group purchasing organization practice of collecting fees from device companies and other suppliers
GPO Safe Harbor Vulnerable? Senate Inquiry Targets Hospital Purchasers
Senators with important ties to health reform negotiations have launched an inquiry into the common hospital group purchasing organization practice of collecting fees from device companies and other suppliers
Masimo Goes Public, Building On Recent Pulse Oximetry Market Share Gains
Pulse oximetry device maker Masimo's successful initial public stock offering Aug. 8 reflects in part the company's ability to capitalize on a doubling of its market share over the past two years